Web based Drug Database (1.07 Linux)

NAPROXEN

Names
Common Name	NAPROXEN
Other Name	NAPROXEN
Pharmacological Group	NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
Chemical Name	(+)-2-(6-Methoxy-2-naphthyl)propionic acid
Chemical Group

Attributes

Indications	Contraindications	Prescriber Cautions	Patient Cautions
Toxicity	Side Effects	Liver Disease	Renal Failure
Pregnancy	Lactation	Pharmacological Actions	Diagnostic Procedures
Drugs	Interactions

Indications

Gout
Dysmenorrhoea
Rheumatoid arthritis
Juvenile rheumatoid arthritis - Still's disease
Osteoarthritis
Ankylosing spondylitis
Musculoskeletal pain
Paediatric use

Contraindications

Asthma
Peptic ulcer
Analgesic allergy
Heart failure
Chronic asthmatic bronchitis
Peptic ulcer of oesophagus
Gastric ulcer
Duodenal ulcer
Peptic ulcer - (PU) site unspecified
Gastrojejunal ulcer
Gastritis and duodenitis
Antirheumatic poisoning
Naproxen poisoning
Adverse reaction to antirheumatics
Adverse reaction to naproxen
Airways obstruction reversible
Non-steroidal anti-inflammatory drugs contraindicated

Prescriber Cautions

Consult current official advice regarding NAPROXEN
Not for infants under 5

Patient Cautions

See information on products containing NAPROXEN for specific advice for patients

Toxicity

- None Listed -

Side Effects

Abdominal discomfort - Common
Constipation - Common
Diarrhoea - Common
Dyspepsia - Common
Epigastric pain - Common
Nausea - Common
Vomiting - Common
Enteritis/colitis - Uncommon
Gastrointestinal haemorrhage - Uncommon
Peptic ulcer symptoms - Uncommon
Perforation of intestine - Uncommon
Acute hepatitis - Rare
Acute pancreatitis - Rare
Agranulocytosis - Rare
Allergic purpura - Rare
Aplastic anaemia - Rare
Bullous eruption - Rare
Chemical oesophagitis - Rare
Ecchymoses - Rare
Eosinophilia - Rare
Erythema multiforme - Rare
Erythema nodosum - Rare
Excessive sweating - Rare
Haemolytic anaemia - Rare
Itching - Rare
Jaundice - Rare
Leucopenia - Rare
Lichenified skin - Rare
Liver function tests abnormal - Rare
Neutropenia - Rare
Oral aphthae - Rare
Patches of alopecia - Rare
Photosensitiveness - Rare
Pustules - Rare
Stevens-Johnson syndrome - Rare
Systemic lupus erythematosus - Rare
Thrombocytopenia - Rare
Toxic epidermal necrolysis - Rare
Vasculitis - Rare
Acute glomerulonephritis
Acute myocardial infarction
Angioneurotic oedema
Blood in urine - haematuria
Bronchospasm
Cerebral arterial occlusion
Congestive heart failure
Convulsions
Corneal opacity
Depression
Dizziness
Dreams
Drowsiness
Dyspnoea
Excessive thirst
Headache
Hearing difficulty
Hyperkalaemia
Hypertension
Infertility - female
Insomnia
Interstitial nephritis
Light-headedness
Malaise/lethargy
Meningitis - aseptic
Muscle weakness
Myalgia
Nephrotic syndrome
Oedema
Optic neuritis
Optic papillitis
Palpitations
Papilloedema
Poor concentration
Pulmonary oedema
Pyrexia
Rash
Renal function tests abnormal
Serum creatinine raised
Tinnitus
Visual symptoms

Liver Disease

Avoid NAPROXEN in severe liver disease
NAPROXEN causes sodium and water retention in liver disease
NAPROXEN - increased risk of gastrointestinal bleeding in liver disease

Renal Failure

Avoid NAPROXEN if possible in mild renal failure
Manufacturer advises reduce dose of NAPROXEN in renal failure
NAPROXEN - reduces renal function in renal failure
NAPROXEN - sodium and water retention in renal failure

Pregnancy

With regular doses of NAPROXEN - increased risk of closure of fetal ductus arteriosus in utero & possible persistent pulmonary hypertension of the newborn
Delayed onset & increased duration of labour with increased blood loss
Avoid NAPROXEN in the 1st TRIMESTER of pregnancy
Avoid NAPROXEN in the 3rd TRIMESTER of pregnancy
Manufacturer advises toxicity of NAPROXEN in pregnancy in animal studies

Lactation

Although NAPROXEN not known to be harmful in breast feeding some manufacturers advise avoid
Amount of NAPROXEN in breast milk too small to be harmful

Pharmacological Actions

ANALGESIC effect
ANTIINFLAMMATORY effect
ANTIPYRETIC effect
CYCLOOXYGENASE INHIBITOR effect

Diagnostic Procedures

Urine 5-hydroxyindoleacetic acid high

Drugs containing NAPROXEN

NAPROXEN 250mg tablets
NAPROXEN 500mg tablets
NAPROSYN 250mg tablets
NAPROSYN 500mg tablets
FEMINAX ULTRA 250mg tablets
NAPROXEN 250mg e/c tablets
NAPROXEN 500mg e/c tablets
NAPROSYN EC 250mg e/c tablets
NAPROSYN EC 375mg e/c tablets
NAPROSYN EC 500mg e/c tablets
NAPRATEC 500mg/0.2mg tabs 2x56
NAPROX tab+MISOPROST tab pack
NAPROXEN 375mg e/c tablets
NAPROX+MISOP 500mg/200mcg tab
NAPROXEN 125mg/5mL suspension
Naproxen 250mg/5ml oral susp
Naproxen 500mg/5ml oral susp

Interacting Ingredients

ACEBUTOLOL
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of ACEBUTOLOL. Moderate risk. Monitor
ACECLOFENAC
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of ACECLOFENAC. Moderate risk. May need to avoid combination
ACEMETACIN
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of ACEMETACIN. Moderate risk. May need to avoid combination
ACENOCOUMAROL
Theoretical potential for NAPROXEN increasing the ANTICOAGULANT effect of ACENOCOUMAROL. Moderate risk. May need to avoid combination
ALOXIPRIN
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of ALOXIPRIN. Moderate risk. May need to avoid combination
AMINOPHYLLINE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of AMINOPHYLLINE. Moderate risk. Avoid
AMOXICILLIN
Infrequent reports of AMOXICILLIN increasing the NEPHROTOXICITY of NAPROXEN. Usually no risk. Usually no action necessary
ASPIRIN
Likely interaction of ASPIRIN increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
ASPIRIN [RECTUM]
Likely interaction of ASPIRIN [RECTUM] increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
ATENOLOL [ORAL]
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of ATENOLOL [ORAL]. Moderate risk. Monitor
ATENOLOL [PARENTERAL]
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of ATENOLOL [PARENTERAL]. Moderate risk. Monitor
AZAPROPAZONE
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of AZAPROPAZONE. Moderate risk. May need to avoid combination
BAMBUTEROL HYDROCHLORIDE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of BAMBUTEROL HYDROCHLORIDE. Moderate risk. Avoid
BECLOMETASONE [INHALED]
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of BECLOMETASONE [INHALED]. Moderate risk. Avoid
BENORILATE
Likely interaction of BENORILATE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
BETAMETHASONE
Likely interaction of BETAMETHASONE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. Monitor
BETAMETHASONE [INHALED]
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of BETAMETHASONE [INHALED]. Moderate risk. Avoid
BETAXOLOL
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of BETAXOLOL. Moderate risk. Monitor
BISMUTH CHELATE
Likely interaction of NAPROXEN reducing the ULCER HEALING effect of BISMUTH CHELATE. Moderate risk. Avoid
BISOPROLOL FUMARATE
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of BISOPROLOL FUMARATE. Moderate risk. Monitor
BUDESONIDE [GASTROINTESTINAL]
Likely interaction of BUDESONIDE [GASTROINTESTINAL] increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. Monitor
BUDESONIDE [INHALED]
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of BUDESONIDE [INHALED]. Moderate risk. Avoid
BUFYLLINE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of BUFYLLINE. Moderate risk. Avoid
BUMETANIDE
Theoretical potential for NAPROXEN reducing the DIURETIC effect of BUMETANIDE. Moderate risk. Monitor
CANDESARTAN CILEXETIL
Likely interaction of NAPROXEN increasing the NEPHROTOXICITY of CANDESARTAN CILEXETIL. Potential risk. Monitor
CARBENOXOLONE
Likely interaction of NAPROXEN reducing the ULCER HEALING effect of CARBENOXOLONE. Moderate risk. Avoid
CARTEOLOL HYDROCHLORIDE
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of CARTEOLOL HYDROCHLORIDE. Moderate risk. Monitor
CARVEDILOL
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of CARVEDILOL. Moderate risk. Monitor
CELIPROLOL HYDROCHLORIDE
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of CELIPROLOL HYDROCHLORIDE. Moderate risk. Monitor
CHOLINE MAGNESIUM TRISALICYLATE
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of CHOLINE MAGNESIUM TRISALICYLATE. Moderate risk. May need to avoid combination
CHOLINE THEOPHYLLINATE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of CHOLINE THEOPHYLLINATE. Moderate risk. Avoid
CICLOSPORIN
Infrequent reports of NAPROXEN increasing the NEPHROTOXICITY of CICLOSPORIN. Moderate risk. Monitor
CIMETIDINE
Likely interaction of NAPROXEN reducing the ULCER HEALING effect of CIMETIDINE. Moderate risk. Avoid
CINOXACIN
Theoretical potential for NAPROXEN increasing the CONVULSANT effect of CINOXACIN. Potential risk. May need to avoid combination
CIPROFLOXACIN
Theoretical potential for NAPROXEN increasing the CONVULSANT effect of CIPROFLOXACIN. Potential risk. May need to avoid combination
CLOPIDOGREL
Theoretical potential for NAPROXEN increasing the PLATELET ANTAGONIST effect of CLOPIDOGREL. Moderate risk. May need to avoid combination
CORTISONE ACETATE
Likely interaction of CORTISONE ACETATE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. Monitor
CROMOGLICATE [INHALED]
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of CROMOGLICATE [INHALED]. Moderate risk. Avoid
DANAPAROID SODIUM
Theoretical potential for NAPROXEN increasing the ANTICOAGULANT effect of DANAPAROID SODIUM. Moderate risk. May need to avoid combination
DEGLYCYRRHIZINISED LIQUORICE
Likely interaction of NAPROXEN reducing the ULCER HEALING effect of DEGLYCYRRHIZINISED LIQUORICE. Moderate risk. Avoid
DEXAMETHASONE [ORAL]
Likely interaction of DEXAMETHASONE [ORAL] increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. Monitor
DEXAMETHASONE [PARENTERAL]
Likely interaction of DEXAMETHASONE [PARENTERAL] increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. Monitor
DEXIBUPROFEN
Likely interaction of DEXIBUPROFEN increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
DEXKETOPROFEN
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of DEXKETOPROFEN. Moderate risk. May need to avoid combination
DICLOFENAC POTASSIUM
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
DICLOFENAC SODIUM [ORAL]
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of DICLOFENAC SODIUM [ORAL]. Moderate risk. May need to avoid combination
DICLOFENAC SODIUM [PARENTERAL]
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of DICLOFENAC SODIUM [PARENTERAL]. Moderate risk. May need to avoid combination
DICLOFENAC SODIUM [RECTUM]
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of DICLOFENAC SODIUM [RECTUM]. Moderate risk. May need to avoid combination
DIFLUNISAL
Likely interaction of DIFLUNISAL increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
DIPROPHYLLINE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of DIPROPHYLLINE. Moderate risk. Avoid
ENOXACIN
Theoretical potential for NAPROXEN increasing the CONVULSANT effect of ENOXACIN. Potential risk. May need to avoid combination
ENOXAPARIN
Likely interaction of NAPROXEN increasing the ANTICOAGULANT effect of ENOXAPARIN. Moderate risk. May need to avoid combination
EPHEDRINE HYDROCHLORIDE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of EPHEDRINE HYDROCHLORIDE. Moderate risk. Avoid
EPROSARTAN
Likely interaction of NAPROXEN increasing the NEPHROTOXICITY of EPROSARTAN. Potential risk. Monitor
ESMOLOL HYDROCHLORIDE
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of ESMOLOL HYDROCHLORIDE. Moderate risk. Monitor
ESOMEPRAZOLE
Likely interaction of NAPROXEN reducing the ULCER HEALING effect of ESOMEPRAZOLE. Moderate risk. Avoid
ETODOLAC
Likely interaction of ETODOLAC increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
FAMOTIDINE
Likely interaction of NAPROXEN reducing the ULCER HEALING effect of FAMOTIDINE. Moderate risk. Avoid
FENBUFEN
Likely interaction of FENBUFEN increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
FENOPROFEN
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of FENOPROFEN. Moderate risk. May need to avoid combination
FENOTEROL HYDROBROMIDE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of FENOTEROL HYDROBROMIDE. Moderate risk. Avoid
FLUDROCORTISONE ACETATE
Likely interaction of FLUDROCORTISONE ACETATE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. Monitor
FLURBIPROFEN
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of FLURBIPROFEN. Moderate risk. May need to avoid combination
FLURBIPROFEN [RECTUM]
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of FLURBIPROFEN [RECTUM]. Moderate risk. May need to avoid combination
FLUTICASONE [INHALED]
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of FLUTICASONE [INHALED]. Moderate risk. Avoid
FONDAPARINUX SODIUM
Likely interaction of NAPROXEN increasing the ANTICOAGULANT effect of FONDAPARINUX SODIUM. Moderate risk. May need to avoid combination
FORMOTEROL
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of FORMOTEROL. Moderate risk. Avoid
FUROSEMIDE
Likely interaction of NAPROXEN reducing the HYPOTENSIVE effect of FUROSEMIDE. Moderate risk. Monitor
GREPAFLOXACIN
Theoretical potential for NAPROXEN increasing the CONVULSANT effect of GREPAFLOXACIN. Potential risk. May need to avoid combination
HYDROCORTISONE
Likely interaction of HYDROCORTISONE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. Monitor
HYDROCORTISONE SODIUM PHOSPHATE
Likely interaction of HYDROCORTISONE SODIUM PHOSPHATE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. Monitor
HYDROCORTISONE SODIUM SUCCINATE
Likely interaction of HYDROCORTISONE SODIUM SUCCINATE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. Monitor
IBUPROFEN
Likely interaction of IBUPROFEN increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
IBUPROFEN LYSINE
Likely interaction of IBUPROFEN LYSINE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
INDACATEROL
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of INDACATEROL. Moderate risk. Avoid
INDOMETACIN
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of INDOMETACIN. Moderate risk. May need to avoid combination
INDOMETACIN [RECTUM]
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
IRBESARTAN
Likely interaction of NAPROXEN increasing the NEPHROTOXICITY of IRBESARTAN. Potential risk. Monitor
ISOETARINE HYDROCHLORIDE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of ISOETARINE HYDROCHLORIDE. Moderate risk. Avoid
ISOPRENALINE HYDROCHLORIDE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of ISOPRENALINE HYDROCHLORIDE. Moderate risk. Avoid
ISOPRENALINE SULPHATE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of ISOPRENALINE SULPHATE. Moderate risk. Avoid
KETOPROFEN
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of KETOPROFEN. Moderate risk. May need to avoid combination
KETOPROFEN [RECTUM]
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of KETOPROFEN [RECTUM]. Moderate risk. May need to avoid combination
KETOROLAC TROMETAMOL
Likely interaction of NAPROXEN increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
KETOTIFEN
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of KETOTIFEN. Moderate risk. Avoid
LABETALOL HYDROCHLORIDE
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of LABETALOL HYDROCHLORIDE. Moderate risk. Monitor
LANSOPRAZOLE
Likely interaction of NAPROXEN reducing the ULCER HEALING effect of LANSOPRAZOLE. Moderate risk. Avoid
LEVOFLOXACIN
Theoretical potential for NAPROXEN increasing the CONVULSANT effect of LEVOFLOXACIN. Potential risk. May need to avoid combination
LITHIUM CARBONATE
Likely interaction of NAPROXEN increasing the SERUM LEVEL of LITHIUM CARBONATE. Potential risk. Monitor
LITHIUM CHLORIDE [PARENTERAL]
Likely interaction of NAPROXEN increasing the SERUM LEVEL of LITHIUM CHLORIDE [PARENTERAL]. Potential risk. Monitor
LITHIUM CITRATE
Likely interaction of NAPROXEN increasing the SERUM LEVEL of LITHIUM CITRATE. Potential risk. Monitor
LOSARTAN POTASSIUM
Likely interaction of NAPROXEN increasing the NEPHROTOXICITY of LOSARTAN POTASSIUM. Potential risk. Monitor
LYSINE ASPIRIN
Likely interaction of LYSINE ASPIRIN increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
MEFENAMIC ACID
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
MELOXICAM
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of MELOXICAM. Moderate risk. May need to avoid combination
MELOXICAM [RECTUM]
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
MESALAZINE
Theoretical potential for NAPROXEN increasing the NEPHROTOXICITY of MESALAZINE. Potential risk. May need to avoid combination
METHYLEPHEDRINE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of METHYLEPHEDRINE. Moderate risk. Avoid
METHYLPREDNISOLONE
Likely interaction of METHYLPREDNISOLONE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. Monitor
METOPROLOL FUMARATE
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of METOPROLOL FUMARATE. Moderate risk. Monitor
METOPROLOL TARTRATE
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of METOPROLOL TARTRATE. Moderate risk. Monitor
MIFEPRISTONE
Theoretical potential for NAPROXEN increasing the PROSTANERGIC effect of MIFEPRISTONE. Potential risk. Avoid
MISOPROSTOL
Infrequent reports of MISOPROSTOL increasing the CNS TOXICITY of NAPROXEN. Usually no risk. Usually no action necessary
MONTELUKAST
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of MONTELUKAST. Moderate risk. Avoid
NABUMETONE
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
NADOLOL
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of NADOLOL. Moderate risk. Monitor
NALIDIXIC ACID
Theoretical potential for NAPROXEN increasing the CONVULSANT effect of NALIDIXIC ACID. Potential risk. May need to avoid combination
NAPROXEN SODIUM
Likely interaction of NAPROXEN SODIUM increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
NEDOCROMIL SODIUM
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of NEDOCROMIL SODIUM. Moderate risk. Avoid
NIZATIDINE
Likely interaction of NAPROXEN reducing the ULCER HEALING effect of NIZATIDINE. Moderate risk. Avoid
NORFLOXACIN
Theoretical potential for NAPROXEN increasing the CONVULSANT effect of NORFLOXACIN. Potential risk. May need to avoid combination
OFLOXACIN
Theoretical potential for NAPROXEN increasing the CONVULSANT effect of OFLOXACIN. Potential risk. May need to avoid combination
OLMESARTAN MEDOXOMIL
Likely interaction of NAPROXEN increasing the NEPHROTOXICITY of OLMESARTAN MEDOXOMIL. Potential risk. Monitor
OMEPRAZOLE [ORAL]
Likely interaction of NAPROXEN reducing the ULCER HEALING effect of OMEPRAZOLE [ORAL]. Moderate risk. Avoid
OMEPRAZOLE [PARENTERAL]
Likely interaction of NAPROXEN reducing the ULCER HEALING effect of OMEPRAZOLE [PARENTERAL]. Moderate risk. Avoid
ORCIPRENALINE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of ORCIPRENALINE. Moderate risk. Avoid
ORCIPRENALINE [INHALED]
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of ORCIPRENALINE [INHALED]. Moderate risk. Avoid
OXPRENOLOL HYDROCHLORIDE
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of OXPRENOLOL HYDROCHLORIDE. Moderate risk. Monitor
PANTOPRAZOLE
Likely interaction of NAPROXEN reducing the ULCER HEALING effect of PANTOPRAZOLE. Moderate risk. Avoid
PENBUTOLOL SULPHATE
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of PENBUTOLOL SULPHATE. Moderate risk. Monitor
PHENINDIONE
Theoretical potential for NAPROXEN increasing the ANTICOAGULANT effect of PHENINDIONE. Moderate risk. May need to avoid combination
PHENYLBUTAZONE
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of PHENYLBUTAZONE. Moderate risk. May need to avoid combination
PINDOLOL
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of PINDOLOL. Moderate risk. Monitor
PIRBUTEROL
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of PIRBUTEROL. Moderate risk. Avoid
PIROXICAM
Likely interaction of PIROXICAM increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
PIROXICAM [RECTUM]
Likely interaction of PIROXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
PIROXICAM-BETADEX
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of PIROXICAM-BETADEX. Moderate risk. May need to avoid combination
PRACTOLOL
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of PRACTOLOL. Moderate risk. Monitor
PREDNISOLONE
Likely interaction of PREDNISOLONE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. Monitor
PREDNISOLONE ACETATE
Likely interaction of PREDNISOLONE ACETATE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. Monitor
PREDNISOLONE SODIUM PHOSPHATE
Likely interaction of PREDNISOLONE SODIUM PHOSPHATE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. Monitor
PREDNISONE
Likely interaction of PREDNISONE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. Monitor
PROBENECID
Likely interaction of PROBENECID increasing the SERUM LEVEL of NAPROXEN. Usually no risk. Usually no action necessary
PROPRANOLOL HYDROCHLORIDE
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of PROPRANOLOL HYDROCHLORIDE. Moderate risk. Monitor
RABEPRAZOLE
Likely interaction of NAPROXEN reducing the ULCER HEALING effect of RABEPRAZOLE. Moderate risk. Avoid
RANITIDINE
Likely interaction of NAPROXEN reducing the ULCER HEALING effect of RANITIDINE. Moderate risk. Avoid
RANITIDINE BISMUTH CITRATE
Likely interaction of NAPROXEN reducing the ULCER HEALING effect of RANITIDINE BISMUTH CITRATE. Moderate risk. Avoid
REPROTEROL HYDROCHLORIDE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of REPROTEROL HYDROCHLORIDE. Moderate risk. Avoid
RIMITEROL HYDROBROMIDE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of RIMITEROL HYDROBROMIDE. Moderate risk. Avoid
RITODRINE HYDROCHLORIDE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of RITODRINE HYDROCHLORIDE. Moderate risk. Avoid
ROSOXACIN
Theoretical potential for NAPROXEN increasing the CONVULSANT effect of ROSOXACIN. Potential risk. May need to avoid combination
SALBUTAMOL
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of SALBUTAMOL. Moderate risk. Avoid
SALBUTAMOL [INHALED]
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of SALBUTAMOL [INHALED]. Moderate risk. Avoid
SALICYLAMIDE
Likely interaction of SALICYLAMIDE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
SALIX
Likely interaction of SALIX increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
SALMETEROL XINAFOATE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of SALMETEROL XINAFOATE. Moderate risk. Avoid
SALSALATE
Likely interaction of SALSALATE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
SODIUM SALICYLATE
Likely interaction of SODIUM SALICYLATE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
SOTALOL HYDROCHLORIDE
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of SOTALOL HYDROCHLORIDE. Moderate risk. Monitor
SUCRALFATE
Likely interaction of NAPROXEN reducing the ULCER HEALING effect of SUCRALFATE. Moderate risk. Avoid
SULINDAC
Likely interaction of SULINDAC increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
TELMISARTAN
Likely interaction of NAPROXEN increasing the NEPHROTOXICITY of TELMISARTAN. Potential risk. Monitor
TEMAFLOXACIN
Theoretical potential for NAPROXEN increasing the CONVULSANT effect of TEMAFLOXACIN. Potential risk. May need to avoid combination
TENOXICAM
Likely interaction of TENOXICAM increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
TERBUTALINE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of TERBUTALINE. Moderate risk. Avoid
TERBUTALINE [INHALED]
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of TERBUTALINE [INHALED]. Moderate risk. Avoid
THEOPHYLLINE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of THEOPHYLLINE. Moderate risk. Avoid
TIAPROFENIC ACID
Likely interaction of TIAPROFENIC ACID increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
TIMOLOL
Infrequent reports of NAPROXEN reducing the HYPOTENSIVE effect of TIMOLOL. Moderate risk. Monitor
TINZAPARIN SODIUM
Likely interaction of NAPROXEN increasing the ANTICOAGULANT effect of TINZAPARIN SODIUM. Moderate risk. May need to avoid combination
TOLFENAMIC ACID
Likely interaction of TOLFENAMIC ACID increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
TOLMETIN
Likely interaction of TOLMETIN increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
TORASEMIDE
Theoretical potential for NAPROXEN reducing the DIURETIC effect of TORASEMIDE. Moderate risk. Monitor
TRIAMCINOLONE ACETONIDE
Likely interaction of TRIAMCINOLONE ACETONIDE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. Monitor
TULOBUTEROL HYDROCHLORIDE
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of TULOBUTEROL HYDROCHLORIDE. Moderate risk. Avoid
VALSARTAN
Likely interaction of NAPROXEN increasing the NEPHROTOXICITY of VALSARTAN. Potential risk. Monitor
WARFARIN SODIUM
Theoretical potential for NAPROXEN increasing the ANTICOAGULANT effect of WARFARIN SODIUM. Moderate risk. May need to avoid combination
ZAFIRLUKAST
Infrequent reports of NAPROXEN reducing the BRONCHODILATOR effect of ZAFIRLUKAST. Moderate risk. Avoid